anti-CD3/anti-EGFR bispecific T-cell engager (Revitope Oncology)

N/A

Report date: 2026/03/19 16:57:15

Base Information

Drug Nameanti-CD3/anti-EGFR bispecific T-cell engager (Revitope Oncology)

Drug Alias NameEGFR x CD3 bispecific T-cell engager (Revitope Oncology)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRevitope Oncology Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRevitope Oncology Inc

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A